Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National ...

In September, 2025, global stakeholders will convene at the United Nations General Assembly for the fourth High-Level Meeting ...